Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
SVRA 
Savara Inc (SVRA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/12/2025: SVRA (3-star) is a STRONG-BUY. BUY since 20 days. Simulated Profits (60.93%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $10.31
1 Year Target Price $10.31
| 4 | Strong Buy |
| 2 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 34.33% | Avg. Invested days 34 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 12/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.41B USD | Price to earnings Ratio - | 1Y Target Price 10.31 |
Price to earnings Ratio - | 1Y Target Price 10.31 | ||
Volume (30-day avg) 8 | Beta 0.22 | 52 Weeks Range 1.89 - 7.00 | Updated Date 12/13/2025 |
52 Weeks Range 1.89 - 7.00 | Updated Date 12/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.53 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -39.67% | Return on Equity (TTM) -78.74% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1317510844 | Price to Sales(TTM) 131146 |
Enterprise Value 1317510844 | Price to Sales(TTM) 131146 | ||
Enterprise Value to Revenue 11.91 | Enterprise Value to EBITDA -4.76 | Shares Outstanding 203467845 | Shares Floating 118107332 |
Shares Outstanding 203467845 | Shares Floating 118107332 | ||
Percent Insiders 4.66 | Percent Institutions 83.53 |
About Savara Inc
Exchange NASDAQ | Headquaters Langhorne, PA, United States | ||
IPO Launch date 2017-06-01 | Chairman & CEO Mr. Matthew Pauls J.D., M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 59 | Website https://www.savarapharma.com |
Full time employees 59 | Website https://www.savarapharma.com | ||
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in 2007 and is headquartered in Langhorne, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.